Short-sellers have placed bets on the decline of various coronavirus vaccine developers throughout the vaccine race. Short positions were particularly high from July through November of last year. In this Motley Fool Live video recorded on Feb. 26, 2021, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss whether the trend will continue -- or whether investors today are more confident about Moderna (MRNA 1.90%) and other vaccine stocks.

10 stocks we like better than Moderna Inc.
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Moderna Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of February 24, 2021

 

Corinne Cardina: Now we are going to talk, of course, about GameStop (GME -4.41%). No, I'm just kidding. There's a little bit of a tie-in here, but we're not going to talk about GameStop.

Obviously, the short squeeze with GameStop brought the subject of short-selling to the forefront of a lot of investors' minds. The short squeeze is when investors are betting on a stock's decline.

The short positions in vaccine developers such as Moderna, Novavax (NVAX 0.81%), and Vaxart (VXRT -4.10%), they all rose last year. Those levels are coming down. But in the case of Vaxart, the short positions are still pretty high -- about 36% percent of float. Should investors in vaccine stocks be worried about the level of short positions?

I've been putting your articles in the chat for folks who want to learn more on these things we're just touching on really briefly. But check out the article there, folks, if you want to know more.

What should we know about Vaxart and short squeezes?

Adria Cimino: Well, I think it could be an issue for some of the riskier players. I think it could be an issue for ones that really are at a stage where they have important data coming out, and we're not sure if they're really going to be able to move forward with their product or not. Vaxart might still face some short-selling, and certain other companies might as well.

But I think a lot of the companies like Moderna is probably past that stage right now, I think the betting phase is over on a lot of the ones that are closer to commercialization. That's good news for a lot of the stocks in this space.